Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RUNX1T1
REST API REST API
Homo sapiens
RUNX1T1 is differentially expressed in 310 experiments: 191 organism parts: cerebellum, brain, ... (189 more);, 255 disease states: normal, prostate carcinoma, ... (253 more);, 97 cell types 400 cell lines 36 compound treatments and 83 other conditions.
Synonyms CBFA2T1, ZMYND2, AML1T1, ETO, MTG8, CDR
Orthologs RUNX1T1 (Gallus gallus)   runx1t1 (Danio rerio)   Runx1t1 (Rattus norvegicus)   RUNX1T1 (Bos taurus)   Runx1t1 (Mus musculus)   nvy (Drosophila melanogaster)   runx1t1 (Xenopus laevis)   RUNX1T1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, regulation of DNA binding, transcription, DNA-dependent, generation of precursor metabolites and energy, metal ion binding, identical protein binding, nucleus, protein homodimerization activity, zinc ion binding, fat cell differentiation, sequence-specific DNA binding transcription factor activity
InterPro Term Znf_MYND, MTG8, ETO, TAFH_NHR1, NHR2
UniProt Accession Q9HBV9, Q8TDW8, Q06455, Q7Z4J5, E7EQ59, E5RFQ3, E5RG85, E7EPN4, E7EQW7, E7EQW3, E7EQJ1, E7EQI9, E7ESA9, E7ERJ9, E5RJB3, E5RJE7, E7ETA8, E5RJ32, E7ESL1, E5RK76, E5RH72, E5RH30, E7EV92, E7EWJ9, E5RI38, E5RHJ8, E7EX23
Gene-Disease Assocation COLORECTAL CANCER; CRC
Search EB-eye ENSG00000079102
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (35 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, ... (33 experiments)

Factor Value U/D Experiments
MCF-10A
2
E-TABM-420, E-GEOD-14990
MCF-7
2
E-GEOD-20081, E-GEOD-5823
Raji
2
E-MTAB-37, E-GEOD-96
SW480
2
E-MEXP-1014, E-MTAB-37
U87
2
E-MEXP-903, E-GEOD-20089
CMLT1
1
E-MTAB-37
394 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-360, ... (48 experiments)

Factor Value U/D Experiments
CD14+ monocyte
3
2
E-TABM-145, E-AFMX-5
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
fibroblast
2
E-GEOD-3204, E-GEOD-3920
hematopoietic progenitor cells
1
E-MEXP-70
Leukocytes
1
E-GEOD-21909
M1 macrophage
1
E-GEOD-5099
91 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (79 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
prostate carcinoma
1
4
E-MEXP-2034, E-MTAB-62, E-GEOD-96, E-GEOD-7307, E-GEOD-5377 ... (5 experiments)
colon carcinoma
3
E-MTAB-37, E-MTAB-62, E-MTAB-57
uterine fibroid
3
E-MTAB-62, E-GEOD-7307, E-GEOD-2724
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
rheumatoid arthritis
2
E-GEOD-1919, E-GEOD-7307
249 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5258, E-GEOD-5824, E-TABM-868, E-GEOD-5099, ... (21 experiments)

Factor Value U/D Experiments
none
1
6
E-GEOD-412, E-TABM-868, E-GEOD-5824, E-GEOD-7307, E-GEOD-1919, ... (7 experiments)
valproic acid
1
E-GEOD-1615
FLAP
1
1
E-GEOD-3202
ionomycin
1
E-GEOD-7307
4,5-dianilinophthalimide
2
1
E-GEOD-5258
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
30 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
86 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-1563, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-MEXP-2359, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, E-GEOD-22541, ... (11 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (8 experiments)

Genotype
studied in E-GEOD-2152, E-TABM-1029, E-MEXP-1437, E-GEOD-3494, E-GEOD-2466, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-GEOD-9764, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-26, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-MEXP-561, E-GEOD-980

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-TABM-130, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-GEOD-3485, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-18995

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-4883

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, ... (7 experiments)

Tumor size
studied in E-GEOD-8167, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.434 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM